Bidirectional Link ID'd for Autoimmune Disease, Perinatal Depression

2024-01-19
临床结果
FRIDAY, Jan. 19, 2024 -- There is a bidirectional association between autoimmune disease (AD) and perinatal depression (PND), according to a study published online Jan. 9 in Molecular Psychiatry.
Emma Bränn, from the Karolinska Institutet in Stockholm, and colleagues examined the bidirectional association between PND and AD using nationwide Swedish population and health registers. A total of 55,299 incident PND cases were included, as well as their unaffected full sisters, and 10 unaffected matched women per PND case. Forty-one subtypes of AD diagnoses were identified from the registers.
The researchers found that women with an AD had an increased risk for subsequent PND (odds ratio, 1.30), and women exposed to PND had an increased risk for subsequent AD (odds ratio, 1.30). Comparing exposed women with their unaffected sisters yielded comparable associations (nested case-control odds ratio, 1.3; matched cohort hazard ratio, 1.3); associations were also comparable when studying antepartum and postpartum depression. Women without psychiatric comorbidities had a more pronounced bidirectional association (nested case-control odds ratio, 1.5; matched cohort hazard ratio, 1.4), with the strongest association seen for multiple sclerosis (nested case-control odds ratio, 2.0; matched cohort hazard ratio, 1.8).
"These findings have implications for research on biological mechanisms, and for health care professionals who need to be alert to the risk of PND in women with AD, and vice versa," the authors write.
Abstract/Full Text
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
靶点
-
药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。